MedTrace Logo

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ADC3680B in Healthy Volunteers

NCT01173770 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2011-02-02

No results posted yet for this study

Summary

This is a First-In-Man study designed to examine the safety, tolerability, pharmacokinetics and functional activity of ADC3680B after single and multiple doses in healthy male volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ADC3680B

Escalating single doses ADC3680B or Placebo over 5 study periods

DRUG

ADC3680B

ADC3680B or Placebo for 7 days

DRUG

ADC3680B

Single doses ADC3680B over 2 study periods under fasted and fed conditions

Sponsors & Collaborators

  • Pulmagen Therapeutics

    lead INDUSTRY

Principal Investigators

  • Febbraro · Simbec Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01173770 on ClinicalTrials.gov